Prognostic importance of comorbidity in a hospital-based cancer registry.
about
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosisHematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTThe impact of comorbidity on cancer and its treatmentConsideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review.Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and NeckImpact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study.Patterns of Care for Metastatic Colorectal Cancer in Appalachia, and the Clinical, Sociodemographic, and Service Provider Determinants.Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors.Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerDisparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study.Facility-level analysis of PET scanning for staging among US veterans with non-small cell lung cancer.Patient preference and contraindications in measuring quality of care: what do administrative data miss?Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial.Nativity disparities in late-stage diagnosis and cause-specific survival among Hispanic women with invasive cervical cancer: an analysis of Surveillance, Epidemiology, and End Results dataIdentifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival.Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trialUtilizing national patient-register data to control for comorbidity in prognostic studies.Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.Patients with soft tissue sarcoma comprise a higher probability of comorbidities than cancer-free individuals. A secondary data analysis.A decision-analytic approach to define poor prognosis patients: a case study for non-seminomatous germ cell cancer patientsCancer-associated thrombosis.The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort studyRandomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.Can patient comorbidities be included in clinical performance measures for radiation oncology?HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome.Association between oestrogens receptor expressions in breast cancer and comorbidities: a cross-sectional, population-based study.Discordance in perceived risk and epidemiological outcomes of prostate cancer among African American menInteractions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.An inference method from multi-layered structure of biomedical dataDefinitive Intensity-modulated Radiation Therapy in Elderly Patients with Locally Advanced Oropharyngeal Cancer.Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study.Physical activity and male colorectal cancer survival.Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment.Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System.Does comorbidity explain the ethnic inequalities in cervical cancer survival in New Zealand? A retrospective cohort studyQuality of life in a prospective cohort of elderly women with and without cancer.Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancerEarly dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.
P2860
Q24607442-3A2AE60F-BD0A-4779-AAE3-151F78E8F1F0Q24685958-76702BB1-1E3D-48D4-ABDF-D28306732DA3Q26764935-8F6A0F19-65AD-436C-AA14-AA78CDEC2A73Q27690236-D5F8EA53-DF48-4E9C-B5BF-7359B7309760Q28076894-0C3D21FF-4056-47B9-98C2-5CE5E459F80DQ30275205-C660F08B-EFA2-4492-913C-7A8B257A0B97Q30278908-D7BBEB30-A8CC-47F3-9BA7-5C880E1711F5Q30301315-CF0D35E7-D50B-4D5B-ACC7-23648C7CA90FQ30418160-66B671C2-935B-4586-8AF1-86BD5072C06BQ30422446-20C18EDD-D216-4294-B44F-C7522A5017C9Q30500194-2DECB58E-9746-41C8-ABBB-3539E5B886ACQ30575227-46E0B12B-160E-40A4-9587-06BE22D35582Q30644505-4A7CCA4A-F1B7-4A83-A0B6-663F508F7F1FQ30651467-A07C2872-7CCC-41C0-A5BC-F9F3577A1569Q30660801-666346B4-8787-4093-8212-6B76A41A9351Q30719268-F5E3BD0F-04C0-45BC-BB57-6719EB1C363BQ30791827-F0E391AF-D41C-42AF-B2B2-85FB5CD634FBQ30867393-B4E14054-0C83-4F92-92DE-3B35CC6BD638Q31057366-A87C31AE-0479-498D-9FFC-1F88085AE51EQ31148452-EA31ED71-EB4F-483D-82D5-3CAD9A234A28Q33313043-EE685B14-7BCB-4956-AE8D-E0D520481464Q33389006-B5016A41-873F-4F69-8396-2C63BB0A1DDCQ33432354-CE7B862B-0FDD-4465-A236-C0880B93678BQ33561943-427F1E58-D637-499A-83C4-A5192D2F670AQ33600092-ED708296-BEA2-48B9-B834-E29E9A87CD69Q33611458-A9D0B832-B20E-4403-BE76-78E11781FA27Q33645985-B8CAD40F-B536-4DA1-91C5-4D6005445676Q33652539-66F0D591-8D68-4D5E-B875-1434918CEB28Q33695990-A8F540D5-26F2-4037-865D-1A38BC6D69C7Q33726471-04A37285-F7AB-4BB2-B280-FADD9C4B61A3Q33770819-66B6B9C4-EA48-4ACB-B1F4-79B0EB5E960AQ33772389-171E3189-8150-46F4-B53C-19170884EA11Q33779574-814DB745-4E9B-489D-83AB-F7E4861ECF23Q33816624-078F3283-E4E9-48AB-B29D-CC23F57BAE1FQ33828690-0D474171-2479-44CD-8757-F0EDEBD20DADQ33828862-9D05C09C-0E4A-481D-82C1-87302454A793Q33870527-32563DEF-69F8-427D-BD15-9F994CBBCCDEQ33871574-FF691AA5-98D3-42BA-9FC6-F5ADB0094FBEQ33874673-4CCCC582-3D92-4F50-AB8E-C5B007433862Q33994024-71202F58-3150-411D-8C5A-9A090781697D
P2860
Prognostic importance of comorbidity in a hospital-based cancer registry.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prognostic importance of comorbidity in a hospital-based cancer registry.
@ast
Prognostic importance of comorbidity in a hospital-based cancer registry.
@en
type
label
Prognostic importance of comorbidity in a hospital-based cancer registry.
@ast
Prognostic importance of comorbidity in a hospital-based cancer registry.
@en
prefLabel
Prognostic importance of comorbidity in a hospital-based cancer registry.
@ast
Prognostic importance of comorbidity in a hospital-based cancer registry.
@en
P2093
P356
P1476
Prognostic importance of comorbidity in a hospital-based cancer registry.
@en
P2093
Edward L Spitznagel
Irene Costas
Jay F Piccirillo
Lori Grove
Ryan M Tierney
P304
P356
10.1001/JAMA.291.20.2441
P407
P577
2004-05-01T00:00:00Z